KAIJU Bio
KAIJU Bio is building a software-enabled biotechnology platform for discovering programmable nucleic acid-based targeting systems and precision molecular delivery technologies. The platform operates on a closed-loop design-build-screen-learn cycle, connecting model-guided sequence design with experimental feedback to optimize recognition, delivery, and biological context in tandem. Its delivery work applies AI-enabled screening at massive scale to explore broad distributions of peptide nanoparticle designs for complex in vivo environments.
- Biotechnology
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Healthcare Technology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Conventional therapeutic modalities struggle to address biological targets that require precise molecular recognition and delivery in complex in vivo environments. Existing approaches often optimize single components in isolation, failing to account for how targeting, formulation, biodistribution, and biological context interact, which limits the development of effective in vivo medicines.
Solution
KAIJU Bio is building a software-enabled biotechnology platform for discovering programmable nucleic acid-based targeting systems and precision molecular delivery technologies. The platform operates on a closed-loop design-build-screen-learn cycle, connecting model-guided sequence design with experimental feedback so recognition, delivery, and biological context can be optimized together. It generates sequence-defined targeting systems across vast design spaces, connects nucleic acid design with scalable synthesis workflows, and measures targeting and delivery behavior in disease-relevant human cellular contexts through parallelized multiplexed readouts. Functional data is then used to refine candidate selection and improve subsequent design cycles. The delivery work applies AI-enabled screening at massive scale to explore broad distributions of peptide nanoparticle designs and molecular delivery behaviors, with a distributional approach designed to surface architectures that perform in complex in vivo environments.
Target Audience
Primary customers are biotechnology and pharmaceutical companies developing in vivo nucleic acid therapeutics, as well as research organizations focused on precision molecular delivery and programmable targeting systems for difficult biological targets.
Features
- Model-guided generation of sequence-defined targeting systems across vast design spaces exploring recognition, delivery, and biological context in physiologically relevant systems
- Scalable design and synthesis workflows connecting nucleic acid design with ultra-large experimental search spaces informed by human biology
- Human cell functional screening that measures targeting and delivery behavior in disease-relevant contexts through parallelized multiplexed readouts
- Experimental feedback loops that use functional data to refine candidate selection and improve subsequent design cycles
- AI-enabled screening at massive scale to explore broad distributions of peptide nanoparticle designs and molecular delivery behaviors
- Proprietary infrastructure for connecting sequence design, synthesis planning, screening data, and model refinement across design cycles